U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07572175) titled 'Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity' on April 30.
Brief Summary: This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Anthracycline-induced Cardiotoxicity
Lymphoma
Chemotherapy
Cardiotoxicity
Intervention:
DRUG: Sotagliflozin
Sotagliflozin 400mg starting prior to the first scheduled anthracycline infusion
DRUG: Placebo
Placebo starting prior to the first scheduled anthracycline infusion
Recruitment Status: NOT_YET_RECRUITING
Sponso...